Estradiol + Trenbolone Acetate + Tylosin Tartrate

Verify with FDA CVM →

12 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
10
Deaths Reported
8330.0%
Death Rate

Active Ingredients

EstradiolTrenbolone AcetateTylosin Tartrate

Administration Routes

OtherUnknown

Species Affected

Cattle 11
Unknown 1

Most Affected Breeds

Cattle (unknown) 8
Crossbred Bovine/Cattle 2
Charolais 1
Unknown 1

Most Reported Reactions

Death 10
Pneumonia 8
Unclassifiable adverse event 7
Lameness 5
Flatulence, bloating and distension 4
Peritonitis 3
Bloated 3
Abscess NOS 2
Reticulitis 2
Reduced growth rate 2
Liver failure 2
Loss of condition 1

Outcome Breakdown

Outcome Unknown
10 (50.0%)
Died
10 (50.0%)

Data Summary

Metric Value
Total adverse event reports 12
Reports involving death 10
Case-fatality rate (reported events) 8330.0%
Distinct species in reports 2
Distinct breeds in reports 4
Distinct reactions reported 16
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Estradiol + Trenbolone Acetate + Tylosin Tartrate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 12 adverse event reports referencing Estradiol + Trenbolone Acetate + Tylosin Tartrate, including 10 reports in which the animal died — a 8330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Estradiol, Trenbolone Acetate, Tylosin Tartrate. Reported administration routes include Other, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Estradiol + Trenbolone Acetate + Tylosin Tartrate reports are Cattle (11 reports), Unknown (1 reports), with Cattle accounting for the largest share. Within those species, Cattle (unknown) (8), Crossbred Bovine/Cattle (2), Charolais (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Estradiol + Trenbolone Acetate + Tylosin Tartrate are Death (10), Pneumonia (8), Unclassifiable adverse event (7), Lameness (5). Of the 20 reports with a coded outcome, Outcome Unknown is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Estradiol + Trenbolone Acetate + Tylosin Tartrate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial